Market research
DNLI Denali Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 35.4375
- Dividend yield
- Not available
- Beta
- 1.0
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US24823R1059
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 35.4375
- Dividend yield
- Not available
- Beta
- 1.0
About
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DNLI discussion.
5 years, 4 months ago
Denali Therapeutics Inc is currently in a long term uptrend where the price is trading 16.1% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.4.
Denali Therapeutics Inc's total revenue rose by 6681.1% to $317M since the same quarter in the previous year.
Its net income has increased by 553.3% to $245M since the same quarter in the previous year.
Finally, its free cash flow grew by 1117.0% to $513M since the same quarter in the previous year.
Based on the above factors, Denali Therapeutics Inc gets an overall score of 5/5.